Rep. Mike Gallagher: The Promising Pathway Act means patient access to cutting-edge treatments
Rep. Mike Gallagher: The Promising Pathway Act means patient access to cutting-edge treatments
“There are still thousands of Americans who aren’t getting access to innovative, cutting-edge treatments that they need. That’s what Promising Pathways is all about.”
– U.S. Representative Mike Gallagher (WI)
The FDA’s usual drug approval process takes an average of 10 to 12 years. But thousands of terminally ill Americans do not have the luxury of time—they need access to promising treatments as soon as possible.
That’s why Representative Mike Gallagher (WI) introduced the Promising Pathway Act (PPA). Here, he discusses the need to rethink the FDA’s current process, which he says doesn’t go far enough for many patients.
At FGA, we don’t just talk about changing policy—we make it happen.
By partnering with FGA through a gift, you can create more policy change that returns America to a country where entrepreneurship thrives, personal responsibility is rewarded, and paychecks replace welfare checks.
